Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 20:32:17 16/07/2024 BST 		5-day change 1st Jan Change
2.235 USD +5.42% Intraday chart for Lexicon Pharmaceuticals, Inc. +39.69% +46.08%
04:57pm FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin MT
02:56pm FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin MT
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Lexicon Pharmaceuticals, Inc.

FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin MT
FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin MT
Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure CI
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief MT
Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer CI
Lexicon Pharmaceuticals, Inc. Announces Management Changes CI
Lexicon Enters into A Sixth Amendment to Its Loan and Security Agreement with Oxford Finance LLC CI
Sector Update: Health Care Stocks Gain in Late Afternoon MT
Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy MT
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes CI
Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association CI
HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target MT
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell MT
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction CI
Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target MT
Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire MT
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024 CI
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024 CI
Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients MT

Chart Lexicon Pharmaceuticals, Inc.

Chart Lexicon Pharmaceuticals, Inc.
More charts

Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Sector
Biotechnology & Medical Research
Calendar
31/07/2024 - Q2 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.12 USD
Average target price
6.2 USD
Spread / Average Target
+192.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEXICON PHARMACEUTICALS, INC. Stock Lexicon Pharmaceuticals, Inc.
+46.08% 766M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.31% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.53% 117B
ARGENX SE Stock argenx SE
+25.44% 27.67B
BIONTECH SE Stock BioNTech SE
-17.81% 20.33B
GENMAB A/S Stock Genmab A/S
-15.17% 16.79B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.89% 15.63B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+12.49% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+56.56% 14.43B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. News Lexicon Pharmaceuticals, Inc.
  5. FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin